BIO Cash-Secured Put Strategy
BIO (Bio-Rad Laboratories, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market.
BIO (Bio-Rad Laboratories, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $6.58B, a trailing P/E of 38.89, a beta of 1.06 versus the broader market, a 52-week range of 211.43-343.12, average daily share volume of 335K, a public-listing history dating back to 1980, approximately 8K full-time employees. These structural characteristics shape how BIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.06 places BIO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 38.89 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a cash-secured put on BIO?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current BIO snapshot
As of May 15, 2026, spot at $247.19, ATM IV 36.60%, IV rank 2.58%, expected move 10.49%. The cash-secured put on BIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this cash-secured put structure on BIO specifically: BIO IV at 36.60% is on the cheap side of its 1-year range, which means a premium-selling BIO cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 10.49% (roughly $25.94 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on BIO should anchor to the underlying notional of $247.19 per share and to the trader's directional view on BIO stock.
BIO cash-secured put setup
The BIO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BIO near $247.19, the first option leg uses a $230.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BIO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $230.00 | $5.05 |
BIO cash-secured put risk and reward
- Net Premium / Debit
- +$505.00
- Max Profit (per contract)
- $505.00
- Max Loss (per contract)
- -$22,494.00
- Breakeven(s)
- $224.95
- Risk / Reward Ratio
- 0.022
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
BIO cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on BIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$22,494.00 |
| $54.66 | -77.9% | -$17,028.60 |
| $109.32 | -55.8% | -$11,563.21 |
| $163.97 | -33.7% | -$6,097.81 |
| $218.63 | -11.6% | -$632.41 |
| $273.28 | +10.6% | +$505.00 |
| $327.93 | +32.7% | +$505.00 |
| $382.59 | +54.8% | +$505.00 |
| $437.24 | +76.9% | +$505.00 |
| $491.90 | +99.0% | +$505.00 |
When traders use cash-secured put on BIO
Cash-secured puts on BIO earn premium while a trader waits to acquire BIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning BIO.
BIO thesis for this cash-secured put
The market-implied 1-standard-deviation range for BIO extends from approximately $221.25 on the downside to $273.13 on the upside. A BIO cash-secured put lets a trader earn premium while waiting to acquire BIO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current BIO IV rank near 2.58% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BIO at 36.60%. As a Healthcare name, BIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BIO-specific events.
BIO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BIO alongside the broader basket even when BIO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on BIO carry tail risk when realized volatility exceeds the implied move; review historical BIO earnings reactions and macro stress periods before sizing. Always rebuild the position from current BIO chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on BIO?
- A cash-secured put on BIO is the cash-secured put strategy applied to BIO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With BIO stock trading near $247.19, the strikes shown on this page are snapped to the nearest listed BIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BIO cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the BIO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 36.60%), the computed maximum profit is $505.00 per contract and the computed maximum loss is -$22,494.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BIO cash-secured put?
- The breakeven for the BIO cash-secured put priced on this page is roughly $224.95 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BIO market-implied 1-standard-deviation expected move is approximately 10.49%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on BIO?
- Cash-secured puts on BIO earn premium while a trader waits to acquire BIO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning BIO.
- How does current BIO implied volatility affect this cash-secured put?
- BIO ATM IV is at 36.60% with IV rank near 2.58%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.